CD46/114 #nowplaying

That post-hoc roxa data is ??? And mechanistically in MDS/MF even more ??? Cd46 *may* be interesting but NovaQuest balloon payment big overhang

Relire : Le fameux #clientélisme #lotois : les clans ont la vie dure. Pascal Serre Historique édito Dire Lot youtu.be/PeNNk_tPJWI #cahors #figeac #gourdon #souillac #montcuq #lot46 #prefet46 #cd46

🌈เน็ตฟลิกซ์ จอไทย แพคสูงสุด4k 🍒🪡 — ★ จอส่วนตัว ล็อคได้🔐 7วัน 55.-/ ทีวี 60฿ 30วัน 139.-/ ทีวี 159฿ [แถมแอพฟรี]🎬 — ★ จอหาร🥐 7วัน 35.-/ทีวี 38฿ 30วัน 79.-/ทีวี 85฿ -มีรีวิว -ดูแลหลังการขายเลย❇️ ☎️สั่งซื้อ : lin.ee/UpN88iy #หารnetflix #หารเน็ตฟลิก cd46

Drs. @flavell_rob & @anilbidkar1 sat down with @UrologyTimes to discuss preclinical findings showing that combining CD46-directed alpha radiation with ADC therapy produced superior antitumor activity in prostate cancer models over either treatment alone. urologytimes.com/view/precli…

First in Human CD46-targeted immunoPET imaging with 89Zr-DFO-YS5 in #mCRPC. Presentation by Felicia Tang @UCSF. #SNMMI26 written coverage by @zklaassen_md @GACancerCenter > bit.ly/4x8S3wk @SNM_MI

Stop by the Science Pavilion this evening to see Dr. Anil Bidkar's (@anilbidkar1) poster on optimizing preclinical models of visceral, skeletal & nodal metastatic prostate cancer with CD46-targeted ImmunoPET validation. #SNMMI26 @SNM_MI

Prostate cancer spreads in complex ways: visceral, skeletal & nodal. Finishing day 1 of #SNMMI26 with @UCSFimaging & @UCSF_Ci2's Dr. @anilbidkar1 presenting research on optimizing preclinical models of metastatic prostate cancer & validating with CD46-targeted ImmunoPET. @SNM_MI

Zac Kornberg highlights CD46 as a novel, immunoPET target in staging metastatic bladder cancer now validated in vivo models including orthotopic. Enriched EV resistant cell lines. Already in use via clinical trial for prostate cancer and melanoma @UCSFCancer @flavell_rob

🫁 #WorldAsthmaDay Open‑access research reveals how reduced IL‑10 from FoxP3⁺ Treg cells in allergic eosinophilic asthma may be partially compensated by CD46‑driven FoxP3⁻ IL‑10⁺ regulatory T cells, shedding light on immune balance in asthma. 👉 doi.org/10.1093/cei/uxag017

The California Republican Party is proud to endorse David Pan for CD46.

Beyond PSMA, the target map is expanding. @ProfKHerrmann ACP3, STEAP, DLL3, FAP, B7-H3, CD46 and TROP2 may shape the next theranostic era…. @drlouiseemmett @DrMHofman @stefanofanti4 @CigdemSoydal @OncoAlert @APCCC_Lugano #APCCC26 @BourlonMaite @nataliagandur @Silke_Gillessen @AOmlin @OpenMedicineHQ @MedwatchKate @Ecastromarcos @ravikanesvaran @dmukherji @scserendipity1 @CParkMD @ZilliThomas @urotoday @Uroweb @CaPsurvivorship

⭐ Antibody-drug conjugates in prostate cancer — promise, challenges and what’s next @OncoAlert @APCCC_Lugano #IPCS26 #APCCC26 @Silke_Gillessen @AOmlin Presented by @tompowles1 🔹 Comprehensive and forward-looking overview 🔹 Key insights: • ADCs show activity across multiple targets → PSMA, B7-H3, STEAP1, TROP2, CD46 • Early signals are encouraging → but responses remain heterogeneous • Lessons from bladder cancer → ADCs can become practice-changing in the right setting • Resistance mechanisms are complex → antigen loss, payload resistance, trafficking issues • Linker stability and payload selection are critical determinants of efficacy and toxicity • Combinations (IO, ARPI, chemo) likely key to unlock full potential 🔹 Take-home: ADCs are not yet transformative alone → but they represent a major new therapeutic platform in prostate cancer @Silke_Gillessen @JTheurillat @mishabeltran @bjartell @ChrisSweens1 @DrMHofman @ProfKHerrmann @tompowles1 @EAntonarakis @declangmurphy @VedangMurthy @KOSJ12 @LoebStacy @DrYukselUrun @UrsulaVogl @fabioturco92 @IPCSymposium @RenuEapen @SScagliarini @Tylersbrt @neerajaiims @amerseburger @Cdanicas @AarmstrongDuke @BertrandTOMBAL @DrRanaMcKay @stefanofanti4 @mirrorsmed @profkhermann @dr_coops @piet_ost @_ShankarSiva @DrSpratticus @scocmem @AmandaNizamMD @EUplatinum @Uromigos

⭐ Theranostics for targeted therapy in prostate cancer — beyond PSMA @OncoAlert @APCCC_Lugano #IPCS26 #APCCC26 @Silke_Gillessen @AOmlin Chaired by L. Emmett 🔹 Highly innovative session — expanding the landscape of actionable targets 🔹 Key insights: • Novel targets emerging beyond PSMA → CD46, HK2, GRPR • HK2 shows favorable biology → tumor specificity low off-target uptake • Early data suggest deep and durable PSA responses with next-gen radioligands • Adaptive dosing strategies may optimize efficacy and tolerability • GRPR and other targets open the door to multi-target theranostic approaches 🔹 Take-home: Theranostics is no longer a single-target field → we are moving toward multi-target, personalized radioligand strategies @DrMHofman @ProfKHerrmann @stefanofanti4 @DrYukselUrun #ProstateCancer #UroOncology #Oncology

Why investors are paying attention to Kyntra Bio $KYNB Kyntra Bio is advancing a differentiated biotech story built around a potential first-in-class ADC program in metastatic prostate cancer and a Phase 3-ready oral opportunity in lower-risk MDS anemia. What stands out: • FG-3246 and FG-3180 are advancing in mCRPC, with Phase 2 monotherapy interim results expected in 2H 2026 • FG-3246 targets CD46, a novel tumor-selective target that may offer an androgen receptor-agnostic, non-PSMA approach • Roxadustat represents a Phase 3-ready development opportunity in anemia associated with LR-MDS, with FDA orphan designation granted in December 2025 • $KYNB highlights that its cash runway has been extended into 2028 following the FibroGen China sale Join Kyntra Bio management live at @RedChip’s Biotech Resurgence virtual investor conference this Thursday, April 16. Register now: redchip.news/3OiG2CW $KYNB $SXTP $INAB $DMAC $BIVI $BFRG $NSRX $CLDI $NXL $GTBP $LTRN $ANIX

8. Complement Activation Persistence Paper says: “Persistent complement activation described in Long COVID” (Table 2, ref 213). Vilobelimab (anti-C5a) improved outcomes. HBP framework: Complement regulators (CD55/DAF, CD46/MCP, CD59) are GPI-anchored or transmembrane glycoproteins. Their surface expression and function depend on proper glycosylation. HBP failure → improper glycosylation of complement regulators → loss of complement control → persistent activation. Blocking C5a treats the consequence, not the cause.

Measles has shown to reset the immune system while also attacking cancers. •The virus uses the CD46 receptor, which is often overexpressed in cancer cells compared to normal cells, as a gateway to enter and infect, says the National Institutes of Health. •Fusogenic Mechanism (Syncytia): The virus causes cancer cells to join together (fusing membranes) and form large, non-viable multinational cells called syncytia, which eventually burst, as described by this article from Vyriad. •Immunogenic Cell Death: As cancer cells break down (lyse), they release antigens that alert the immune system, leading to a broader attack by T-cells, macrophages, and neutrophils against remaining cancer cells.

🎶いよいよ来週放送です🎶 3月16日(月)〜20日(金) 午前6:00 NHK-FM「#古楽の楽しみ」 案内役を務めさせていただきます。 ニューヨークからスーツケースに私物のCD46枚を詰め込み、収録に臨みました。 お楽しみいただけましたら嬉しいです。 ※聞き逃し配信はありませんのでお気をつけください📻